# GLOW peptide: The GHK-Cu + BPC-157 + TB-500 Research Blend, Read Plainly

> GLOW peptide is a non-standardized research blend of GHK-Cu, BPC-157 and TB-500. A chalkboard reading of what each constituent's literature shows and where the blend has no data of its own.

Not a single approved drug. A non-standardized combination with no controlled trial of its own, where every benefit traces to one constituent's literature and the honest gaps are chalked in the margin.

## What the GLOW peptide record actually is

GLOW peptide is not a molecule. It is a co-formulated research combination of three distinct peptides — most commonly GHK-Cu, BPC-157 and TB-500 — sold by suppliers for laboratory use and assembled by clinics into a single vial. There is no GLOW molecule to characterize, no GLOW monograph, and no controlled clinical trial of the blend itself for any indication. Read that sentence twice: every claim on this site that sounds like a GLOW claim is, on inspection, a claim about one of its three parts.

That is the whole reason this page exists. The GLOW name resolves consistently across published consumer and clinic sources to the same trio: GHK-Cu (the copper tripeptide that signals dermal matrix synthesis), BPC-157 (a stable pentadecapeptide that is cytoprotective and pro-angiogenic in animal models), and TB-500 (the actin-binding thymosin beta-4 fragment that promotes cell migration) [1][3][5]. A commonly cited research-label ratio is 10 mg BPC-157, 10 mg TB-500 and 50 mg GHK-Cu per vial — a supplier labeling convention, not a clinically validated dose.

We write it up the way a teaching board does. The thesis goes on the board, each constituent's evidence is worked through underneath, and where the data stops — no blend pharmacokinetics, unstudied copper-and-pH compatibility, a TB-500 literature that mostly uses the full-length parent protein — that gap is marked plainly rather than papered over [10]. A 2026 Sports Medicine review that names all three constituents together reaches the same even-handed conclusion: these peptides show favorable tissue-repair outcomes in animal models, but rigorous human safety data are scarce and a gray market operates largely outside regulatory oversight [10].

## What Is the GLOW Blend?

The GLOW blend is the three-peptide combination GHK-Cu + BPC-157 + TB-500, formulated together rather than dosed separately. Each part carries a different mechanism, and the rationale clinics give for combining them is complementary coverage: a matrix-building signal from GHK-Cu, a vascular and cytoprotective signal from BPC-157, and a cell-migration and anti-scarring signal from TB-500 [2][4][5].

GHK-Cu is the copper(II) chelate of glycyl-L-histidyl-L-lysine — the same GHK sequence that occurs within human type I collagen and circulates in plasma, declining with age [1]. As the copper complex it stimulates dermal fibroblasts to synthesize collagen, elastin and glycosaminoglycans [1][2]. BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) derived from a body-protection protein found in gastric juice; in animal models it accelerates connective-tissue repair and up-regulates the VEGFR2 angiogenic pathway [3][4]. TB-500 is the acetylated heptapeptide Ac-LKKTETQ, the actin-binding region of thymosin beta-4 [5].

GLOW is one of a small family of named blends, and the distinctions matter for anyone trying to read the literature accurately. The Wolverine blend is BPC-157 + TB-500 only — no copper peptide. The KLOW blend adds KPV, an anti-inflammatory tripeptide GLOW does not contain. GLOW is specifically the GHK-Cu-bearing trio. You can read [GLOW peptide benefits](/research) constituent by constituent, or jump to the [GLOW peptide reconstitution and stability](/reconstitution-and-stability) notes for why a reconstituted vial turns blue-violet.

## What this site marks, and what it leaves blank

Three numbers frame the honest position. Three peptides in the blend. Zero controlled trials of the blend itself. And a constituent evidence base that is real but uneven — strongest for GHK-Cu's topical skin effects [1][2], well-documented for BPC-157's rodent tissue repair [3][4], and weakest where it matters most for an injectable product: human data for the thymosin beta-4 family largely use the full-length protein, not the TB-500 fragment people actually buy [5][8].

This is a literature digest, organized as a board with a key. A chalk-yellow mark means a finding the constituent literature actually supports. A dusty-pink mark means a gap or a regulatory limit — the things a careful reader should know are unproven for the blend. A blue mark is a verifiable identifier: a CAS number, a PMID, a DOI. Nothing here is a dosing protocol, a vendor recommendation, or a treatment plan.

Where to go next: [the GHK-Cu matrix evidence](/research) for the skin rationale, [GLOW peptide dosage in the research literature](/dosage) for the constituent-level numbers in study framing, [GLOW legal status and compounding access](/legal-status) for the FDA 503A picture, or the [frequently asked questions](/faq) for the reconstitution, color and tolerability questions people ask most.

## What Is GLOW Peptide?

GLOW peptide is not a single molecule but a co-formulated research combination of three peptides, most commonly GHK-Cu, BPC-157 and TB-500. It is a clinic- and supplier-formulated blend, not a regulated drug product, and there are no controlled clinical trials of the blend itself [10]. The evidence base is the literature on each constituent plus the mechanistic rationale for combining them.

## What Does the GLOW Peptide Do?

In research terms the three constituents converge on tissue repair and skin renewal: GHK-Cu signals dermal matrix synthesis [1], BPC-157 is cytoprotective and pro-angiogenic in animal models [3][4], and TB-500 promotes cell migration and reduced scarring [5]. No study has tested the three-peptide blend head-to-head against its parts in humans, so every described effect is a constituent finding, not a blend finding.

## What Does GLOW Peptide Have in It?

Most commonly GHK-Cu (the copper tripeptide glycyl-L-histidyl-L-lysine), BPC-157 (a synthetic stable pentadecapeptide), and TB-500 (the acetylated thymosin beta-4 fragment Ac-LKKTETQ). Exact ratios are formulation-specific and not standardized; a commonly cited research-label ratio is 10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial, which is a supplier convention rather than a validated dose.

## What Peptides Are in the GLOW Blend?

Three: GHK-Cu, BPC-157 and TB-500. The distinct KLOW blend adds KPV; the Wolverine blend is BPC-157 + TB-500 only. GLOW's name resolves consistently to this GHK-Cu + BPC-157 + TB-500 trio across published consumer and clinic sources [10], which is why the copper component — and the blue-violet color it produces on reconstitution — is the blend's signature.

## What Is GLOW Peptide Used For?

In the research literature its constituents are studied for skin and aesthetics (GHK-Cu) [1][2] and for tissue repair and recovery (BPC-157, TB-500) [3][5]. GLOW is a research blend sold by suppliers for laboratory use only; it is not an approved treatment for any condition, and a 2026 review concludes that unapproved peptides of this class show animal-model promise but scarce human data [10].

---

A chalkboard reading of the GLOW peptide blend — each constituent's evidence worked through and every blend-level gap chalked in the margin, with no clinic at the board and nothing here dispensed.